N. Harada

发表

Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.

M. Sakaitani, K. Morikami, N. Shimma, 2014, ACS medicinal chemistry letters.

Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells

S. Yoshiura, N. Harada, Takaaki Fujimura, 2021, Molecular Cancer Therapeutics.

Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression

S. Kurozumi, M. Yamashita, K. Hozumi, 2021, Scientific Reports.

Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion–positive non–small cell lung cancer cells

K. Furugaki, N. Harada, Takaaki Fujimura, 2020, Cancer biology & therapy.

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model

N. Harada, Y. Yamashita-Kashima, K. Yorozu, 2017, Oncology letters.

Predictive markers of capecitabine sensitivity identified from the expression profile of pyrimidine nucleoside-metabolizing enzymes.

N. Harada, Yasuko Sato, K. Mori, 2013, Oncology reports.

Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors

S. Yoshiura, N. Harada, O. Kondoh, 2022, International Journal of Hematology.

Combination Therapy of Capecitabine with Cyclophosphamide as a Second-Line Treatment after Failure of Paclitaxel plus Bevacizumab Treatment in a Human Triple Negative Breast Cancer Xenograft Model

N. Harada, K. Yorozu, Y. Moriya, 2013 .

Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.

N. Harada, Y. Yamashita-Kashima, K. Fujimoto-Ouchi, 2013, Oncology reports.

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells

K. Furugaki, N. Harada, Y. Yoshimura, 2021, Anti-cancer drugs.

Immune cell composition and immunological profiles of the breast cancer microenvironment represented by histologically assessed tumor-infiltrating lymphocytes and PD-L1 expression: A systematic analysis

S. Kurozumi, M. Yamashita, K. Hozumi, 2021 .

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

S. Yoshiura, N. Harada, O. Kondoh, 2022, Molecular Biology Reports.

Fluorine Scanning by Nonselective Fluorination: Enhancing Raf/MEK Inhibition while Keeping Physicochemical Properties.

Noriyuki Furuichi, Masahiro Sakaitani, Nobuo Shimma, 2013, ACS medicinal chemistry letters.

The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.

M. Sakaitani, N. Shimma, Y. Aoki, 2013, Bioorganic & medicinal chemistry letters.

Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models

Y. Kodera, H. Nakanishi, N. Harada, 2020, Anti-cancer drugs.

Chk2‐deficient mice exhibit radioresistance and defective p53‐mediated transcription

E. Appella, Hiroshi Suzuki, M. Nakanishi, 2002, The EMBO journal.

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

K. Furugaki, N. Harada, Y. Yoshimura, 2019, BMC Cancer.

Identification of a checkpoint modulator with synthetic lethality to p53 mutants

M. Nakanishi, M. Tsuchiya, Y. Aoki, 2011, Anti-cancer drugs.

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

N. Rosen, T. Sakai, M. Arisawa, 2013, Cancer research.

Impact of bevacizumab in combination with erlotinib on EGFR‐mutated non–small cell lung cancer xenograft models with T790M mutation or MET amplification

T. Mitsudomi, K. Furugaki, N. Harada, 2016, International journal of cancer.

Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization

K. Hashizume, N. Harada, Y. Yamashita-Kashima, 2014, Gastric Cancer.

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate

R. Higuchi, K. Furugaki, N. Harada, 2019, Cancer Chemotherapy and Pharmacology.

Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.

K. Furugaki, N. Harada, T. Iwai, 2014, Lung cancer.

Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection

K. Hashizume, N. Harada, K. Yorozu, 2022, Pathology international.

Molecular cloning and characterization of antigens expressed on rat tumor vascular endothelial cells

Y. Tsutsumi, S. Nakagawa, T. Mayumi, 2000, International journal of cancer.

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation

S. Yoshiura, N. Harada, Takaaki Fujimura, 2020, Cancer Chemotherapy and Pharmacology.

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

K. Furugaki, N. Harada, Y. Yoshimura, 2019, BMC Cancer.

Melting curve analysis for mutations of EGFR and KRAS.

K. Furugaki, N. Harada, T. Iwai, 2014, Anticancer research.

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation

O. Puig, N. Harada, Y. Yoshimura, 2016, Cancer Chemotherapy and Pharmacology.

[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

S. Stone-Elander, P. Pisa, J. Tessier, 2013, EJNMMI Research.

Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.

Saori J Kaneko, N. Harada, S. Harada, 2015, Molecular and clinical oncology.

Abstract. In the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction cancer, it has been reported that the combination of trastuzumab with capecitabine plus cisplatin, or with 5‐fluorouracil (5-FU) plus cisplatin, significantly increase

Saori J Kaneko, N. Harada, S. Harada, 2015 .

Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model.

Saori J Kaneko, N. Harada, S. Harada, 2015, Molecular and clinical oncology.